Dr. Bruce Johnson has been the leader of the DF/HCC Lung Cancer Program since joining the DFCI in 1998. He became the Chief Clinical Research Officer at DFCI in 2013 and is a member of the DF/HCC Center Scientific Council. He was the Director of the Lowe Center for Thoracic Oncology from 1998 to 2013. Dr. Johnson’s translational research activities are devoted to identifying genomic predictors of the efficacy of targeted agents against lung cancer and other thoracic malignancies. He has received funding for his translational research from a variety of sources, including an R01, a P01 led by Dr. Matthew Meyerson, the past DF/HCC Lung Cancer SPORE grant, the Lung Cancer Mutation Consortium II program led by Dr. Paul Bunn from the University of Colorado and now supported by Free to Breathe, and philanthropic support. His work was recognized internationally when he was awarded the IASLC Scientific Award in 2009. He was a leader of the team awarded the AACR Team Science Award in 2010, and was selected to become a Fellow of the American Society of Clinical Oncology in 2012 and a member of the American Association of Physicians in 2015. Dr. Johnson served on the Board of Directors of the American Society of Clinical Oncology from 2008- 2011 and has been elected as the President of the Society and will begin serving his term in 2017.